Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hirotoshi Okumura"'
Autor:
Iichiro Takata, Hirotoshi Okumura, Hajime Takashima, Ippei Yoshida, Kiyoko Fujita, Katsumasa Otake, Hiroyuki Sugiyama
Publikováno v:
The Journal of Antibiotics. 75:98-107
The emergence of multi-drug resistant pathogenic bacteria, especially Gram-negative bacteria, is a worldwide health problem. New antibiotics directed at previously unexplored targets are urgently needed to overcome resistance to existing antibiotic c
Autor:
Kiyoko Fujita, Iichiro Takata, Ippei Yoshida, Yusuke Honma, Hirotoshi Okumura, Katsumasa Otake, Hajime Takashima, Hiroyuki Sugiyama
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 28(5)
TP0586532 is a novel non-hydroxamate UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) inhibitor. Pharmacokinetic/pharmacodynamic (PK/PD) indices and magnitude of index that correlated with the efficacy of TP0586532 were determined and used to esti
Autor:
Iichiro Takata, Aiko Masuko, Hiroyuki Sugiyama, Fumihito Ushiyama, Hirotoshi Okumura, Hideaki Amada, Kiyoko Fujita
Publikováno v:
Antimicrob Agents Chemother
Gonorrhea is a common, sexually transmitted disease caused by Neisseria gonorrhoeae. Multidrug-resistant N. gonorrhoeae is an urgent threat, and the development of a new antimicrobial agent that functions via a new mechanism is strongly desired. We e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd3cbf3df7c907d819a3c3bc22ce9e09
https://europepmc.org/articles/PMC8097434/
https://europepmc.org/articles/PMC8097434/
Autor:
Yuya Ogata, Nozomi Tanaka-Yamamoto, Naoki Sasamoto, Iichiro Takata, Katsumasa Otake, Hajime Takashima, Yohei Matsuda, Haruhiro Yamashita, Mayumi Endo, Kiyoko Fujita, Kaori Ueki, Masashi Mima, Satoshi Tsuji, Hirotoshi Okumura, Hiroyuki Sugiyama, Fumihito Ushiyama, Risa Kurimoto-Tsuruta
Publikováno v:
Bioorganicmedicinal chemistry. 30
Infectious diseases caused by resistant Gram-negative bacteria have become a serious problem, and the development of therapeutic drugs with a novel mechanism of action and that do not exhibit cross-resistance with existing drugs has been earnestly de
Autor:
Toru Negishi, Hirotoshi Okumura, Katsuhiko Mizuno, Tsuyoshi Yokoi, Nao Nakagawa, Miki Katoh, Miki Nakajima, Takanori Hashizume
Publikováno v:
Drug Metabolism and Disposition. 37:345-351
Cytochrome P450 3A4 is the predominant isoform in liver, and it metabolizes more than 50% of the clinical drugs commonly used. However, CYP3A4 is also responsible for metabolic activation of drugs, leading to liver injury. Benzodiazepines are widely
Autor:
Hirotoshi Okumura, Miki Nakajima, Tsuyoshi Yokoi, Toshihiko Ikeda, Yoshinori Soeno, Katsutoshi Yoshizato, Toshiro Sawada, Miki Katoh, Hikaru Yabuuchi, Chise Tateno
Publikováno v:
Toxicological Sciences. 97:533-538
The liver of a chimeric urokinase-type plasminogen activator (uPA)(+/+)/severe combined immunodeficient (SCID) mouse line recently established in Japan could be replaced by more than 80% with human hepatocytes. We previously reported that the chimeri
Autor:
Chise Tateno, Tomohito Matsui, Miki Nakajima, Shinsaku Naito, Masuhiro Nishimura, Tsuyoshi Yokoi, Hirotoshi Okumura, Miki Katoh, Katsutoshi Yoshizato
Publikováno v:
Drug Metabolism and Disposition. 33:1333-1340
We clarified that major human cytochrome P450 (P450) enzymes were expressed in a chimeric mouse line established recently in Japan, in which the liver could be replaced by more than 80% with human hepatocytes. In this study, we investigated major hum
Publikováno v:
Biochemical pharmacology. 74(3)
Liver dysfunction affects the pharmacokinetics of drugs. The liver plays an important role in drug excretion as well as drug metabolism and pharmacokinetics. In the present study, the relationship between changes in the cefmetazole (CMZ) excretory pa